Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Third-party royalties & milestone payments included in by Quarter
Third-party royalties & milestone payments included in cost of sales ($M) ($M)
Moderna Third-party royalties & milestone payments included in: $11M in Q2 2026, up 83.3% from a year earlier.
Latest, Q2 2026
11
Period ended Jun 30, 2026
Change on a year earlier
+83.3%
6 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
22
Documents cited below
Where the Q2 2026 figure comes from
“Cost of sales for the three months ended June 30, 2026 was $93 million, which included inventory write-downs of $41 million, unutilized manufacturing capacity costs of $23 million, and third-party royalties of $11 million.”
Source: Q2 2026 10-Q ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Third-party royalties & milestone payments included in cost of sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 11 | +83.3% | Q2 2026 10-Q ↗ |
| Q1 2026 | Mar 31, 2026 | 895 | +17,800.0% | Q1 2026 Earnings Release (8-K) ↗ |
| Q4 2025 | Dec 31, 2025 | 34 | -24.4% | Q4 2025 Earnings Release (8-K) ↗ |
| Q3 2025 | Sep 30, 2025 | 43 | -53.3% | Q3 2025 10-Q ↗ |
| Q2 2025 | Jun 30, 2025 | 6 | -40.0% | Q2 2025 Earnings Release (8-K) ↗ |
| Q1 2025 | Mar 31, 2025 | 5 | -37.5% | Q1 2025 10-Q ↗ |
| Q4 2024 | Dec 31, 2024 | 45 | -64.0% | Q4 2024 Earnings Release (8-K) ↗ |
| Q3 2024 | Sep 30, 2024 | 92 | +17.9% | Q3 2024 Earnings Release (8-K) ↗ |
| Q2 2024 | Jun 30, 2024 | 10 | -16.7% | Q2 2024 Earnings Release (8-K) ↗ |
| Q1 2024 | Mar 31, 2024 | 8 | -90.7% | Q1 2024 10-Q ↗ |
| Q4 2023 | Dec 31, 2023 | 125 | -79.3% | Q4 2023 Earnings Release (8-K) ↗ |
| Q3 2023 | Sep 30, 2023 | 78 | -26.4% | Q3 2023 10-Q ↗ |
| Q2 2023 | Jun 30, 2023 | 12 | -92.4% | Q2 2023 10-Q ↗ |
| Q1 2023 | Mar 31, 2023 | 86 | -58.5% | Q1 2023 10-Q ↗ |
| Q4 2022 | Dec 31, 2022 | 604 | +150.6% | Q4 2022 Earnings Release (8-K) ↗ |
| Q3 2022 | Sep 30, 2022 | 106 | -36.9% | Q3 2022 Earnings Release (8-K) ↗ |
| Q2 2022 | Jun 30, 2022 | 157 | +6.1% | Q2 2022 10-Q ↗ |
| Q1 2022 | Mar 31, 2022 | 207 | +146.4% | Q1 2022 10-Q ↗ |
| Q4 2021 | Dec 31, 2021 | 241 | – | Q4 2021 Earnings Release (8-K) ↗ |
| Q3 2021 | Sep 30, 2021 | 168 | – | Q3 2021 Earnings Release (8-K) ↗ |
| Q2 2021 | Jun 30, 2021 | 148 | – | Q2 2021 10-Q ↗ |
| Q1 2021 | Mar 31, 2021 | 84 | – | Q1 2021 10-Q ↗ |
Cite this data
StockData. (2026). Moderna Third-party royalties & milestone payments included in ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/cos-royalties
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.